JAK inhibitors have been hotly pursued by the biopharmaceutical industry as new players in the field of immune-mediated diseases. This year, and with COVID-19 on the top of the agenda for the industry, JAK inhibitors continue to make headlines as potential therapies against this virus.
Interested in delving more into the opportunities this emerging class of therapeutic hold?
The JAK Inhibitors Drug Development Virtual Summit (Wednesday, June 24) is your opportunity to take part in a multi-disciplinary discussion for large pharma, biotech and academic leaders.
Hear live from 13 speakers including:
- Kimberly McHale, Director of Non- Clinical Science & Development Program Leader, Dermavant
- Anabela Cardoso, Global Brand Development Lead – Immunology, Eli Lilly
- Barbara Klencke, Chief Development Officer, Sierra Oncology
- Greg Coffey, Senior Director of Biology & Pharmacology, Portola Pharmaceuticals
Tune into the live stream content and online networking alongside attendees from AbbVie, Activx Biosciences, Bristol-Myers Squibb, Boehringer Ingelheim, Foamix, Pfizer, Regeneron Pharmaceuticals and many more.
Don’t miss our bonus content either! Available for all registered attendees after the conference.
- Dual JAK/ROCK Inhibitors: Moving JAK Inhibition to the New Therapeutic Avenues Where Anti-Inflammation & Anti-Fibrotic Activity is Needed – Maciej Wieczorek, Chief Executive Officer, Celon Pharma
- Tofacitinib Modulates Cardiometabolic & Immunologic Disease Markers Associated with Premature Atherosclerosis in SLE – Sarfaraz Hasni, Director Lupus Clinical Research, National Institute of Arthritis & Musculoskeletal & Skin Diseases National Institutes
- Filgotinib: Maturing the JAK1 Profile – Piet Wigerinck, Chief Scientific Officer, Galapagos
Download the full event guide to learn more.
Tickets are $799 for a limited time only. Buy yours online today.